

A blue horizontal banner with an orange circle on the left side, containing the text 'PRESS RELEASE' in white capital letters.

PRESS RELEASE

## Investor and Press Conference on Today's Announcement Regarding the Acquisition and License Transaction with Idorsia

**Tokyo, Japan and Cambridge, UK, 20 July 2023** – Sosei Group Corporation (“the Company”; TSE: 4565), will hold an investor and press conference on today’s announcement; “Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company.”

The conference will be held in person in Tokyo and virtually at 5pm JST (9am BST) on Thursday 20 July in Tokyo. The meeting is open to all existing and potential investors, sell-/buy-side analysts, and journalists and will consist of a presentation followed by a Q&A session. Please click [here](#) to pre-register, which will provide a link to access the webinar. Simultaneous Japanese/English translation will be provided.

Presentation slides will be made available through the investor section of the Company’s Home Page [here](#). Archive streaming will be available [here](#) on the Company’s website after the event.

-ENDS-

### About Sosei Heptares

Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world-class science to patients globally. Our vision is to become one of Japan’s global biopharmaceutical champions.

Sosei Heptares has a leading development capability and a profitable and growing commercial operation in Japan, which it intends to expand into additional selected markets in the Asia-Pacific region.

Sosei Heptares is advancing a broad and deep pipeline of novel medicines created using its world-leading GPCR-targeted StaR® technology and structure-based drug design platform across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases.

In addition, we have leveraged our unique discovery and development capabilities to establish multiple value-generating partnerships with world-leading biopharmaceutical companies, including AbbVie, Genentech (Roche), GSK, Lilly, Neurocrine Biosciences, Novartis, Pfizer, Sanofi and Takeda.

A solid orange circle on the left side of the page.

## PRESS RELEASE

Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in London and Cambridge, UK.

*“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.*

For more information, please visit <https://soseiheptares.com/>

LinkedIn: [@soseiheptaresco](#) | Twitter: [@soseiheptaresco](#) | YouTube: [@soseiheptaresco](#)

### Enquiries:

#### Sosei Heptares – Media and Investor Relations

Hironoshin Nomura, Chief Financial Officer

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures

Maya Bennison, Communications Manager

+81 (0)3 5210 3399 | +44 (0)1223 949390 | [IR@SoseiHeptares.com](mailto:IR@SoseiHeptares.com)

#### MEDI STRAVA Consulting (for International Media)

Mark Swallow, Frazer Hall

+44 (0)203 928 6900 | [SoseiHeptares@medistrava.com](mailto:SoseiHeptares@medistrava.com)

#### Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Sosei Group Corporation’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.